ASCENDIS PHARMA A/S's ticker is ASND and the CUSIP is 04351P101. A total of 182 filers reported holding ASCENDIS PHARMA A/S in Q1 2022. The put-call ratio across all filers is 0.64 and the average weighting 0.8%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $2,843 | +7.9% | 30,000 | 0.0% | 0.01% | +16.7% |
| Q2 2023 | $2,635 | +22.5% | 30,000 | +50.0% | 0.01% | +20.0% |
| Q1 2023 | $2,151 | -10.8% | 20,000 | 0.0% | 0.01% | -16.7% |
| Q4 2022 | $2,412 | -99.9% | 20,000 | 0.0% | 0.01% | 0.0% |
| Q3 2022 | $2,037,000 | +46.2% | 20,000 | +32.8% | 0.01% | +50.0% |
| Q2 2022 | $1,393,000 | -50.1% | 15,060 | -37.4% | 0.00% | -42.9% |
| Q1 2022 | $2,791,000 | -3.8% | 24,060 | +10.1% | 0.01% | 0.0% |
| Q4 2021 | $2,901,000 | -12.8% | 21,860 | +2.8% | 0.01% | -22.2% |
| Q3 2021 | $3,328,000 | +17.8% | 21,270 | 0.0% | 0.01% | +12.5% |
| Q2 2021 | $2,825,000 | +3.7% | 21,270 | 0.0% | 0.01% | -11.1% |
| Q1 2021 | $2,725,000 | +44.6% | 21,270 | +88.7% | 0.01% | +28.6% |
| Q4 2020 | $1,885,000 | +4.5% | 11,270 | -4.7% | 0.01% | -12.5% |
| Q3 2020 | $1,804,000 | +18.8% | 11,830 | -15.5% | 0.01% | 0.0% |
| Q2 2019 | $1,518,000 | -20.8% | 14,000 | -48.3% | 0.01% | -27.3% |
| Q1 2019 | $1,916,000 | +42.1% | 27,100 | +22.3% | 0.01% | +22.2% |
| Q4 2018 | $1,348,000 | -29.6% | 22,150 | -18.3% | 0.01% | -18.2% |
| Q3 2018 | $1,916,000 | +508.3% | 27,100 | +464.6% | 0.01% | +450.0% |
| Q2 2018 | $315,000 | -76.1% | 4,800 | -76.9% | 0.00% | -77.8% |
| Q1 2018 | $1,319,000 | – | 20,800 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Vivo Capital, LLC | 1,797,745 | $265,886,000 | 19.06% |
| RA Capital Management | 4,914,955 | $726,922,000 | 14.16% |
| Sofinnova Investments, Inc. | 1,109,874 | $164,150,000 | 10.35% |
| Eventide Asset Management | 1,709,848 | $252,887,000 | 5.50% |
| Asymmetry Capital Management, L.P. | 47,599 | $7,040,000 | 5.39% |
| BERYLSON CAPITAL PARTNERS, LLC | 58,200 | $8,608,000 | 5.30% |
| Avoro Capital Advisors LLC | 1,750,000 | $258,825,000 | 5.12% |
| Eversept Partners, LP | 220,344 | $32,588,878 | 4.47% |
| Spyglass Capital Management LLC | 452,104 | $66,866,000 | 4.14% |
| Orbimed Advisors | 1,562,986 | $231,166,000 | 3.25% |